Support for the use of objective comorbidity indices in the assessment of noncancer death risk in prostate cancer patients

Lu, 2011, Charlson and Rx-Risk comorbidity indices were predictive of mortality in the Australian health care setting, J Clin Epidemiol, 64, 223, 10.1016/j.jclinepi.2010.02.015 Vitry, 2009, Validity of medication-based co-morbidity indices in the Australian elderly population, Aust N Z J Public Health, 33, 126, 10.1111/j.1753-6405.2009.00357.x Daskivich, 2010, Severity of comorbidity and non-prostate cancer mortality in men with early-stage prostate cancer, Arch Int Med, 170, 1396, 10.1001/archinternmed.2010.251 Fowler, 2000, Comparison of recommendations by urologists and radiation oncologists for treatment of clinically localized prostate cancer, J Am Med Assoc, 283, 3217, 10.1001/jama.283.24.3217 Albertsen, 2011, Impact of comorbidity on survival among men with localized prostate cancer, J Clin Oncol, 29, 1335, 10.1200/JCO.2010.31.2330 Walz, 2007, Clinicians are poor raters of life-expectancy before radical prostatectomy or definitive radiotherapy for localized prostate cancer, BJU Int, 100, 1254, 10.1111/j.1464-410X.2007.07130.x Naqvi, 2011, Association of comorbidities with overall survival in myelodysplastic syndrome: development of a prognostic model, J Clin Oncol, 29, 2240, 10.1200/JCO.2010.31.3353 Wo, 2009, Evaluating the combined effect of comorbidity and prostate-specific antigen kinetics on the risk of death in men after prostate-specific antigen recurrence, J Clin Oncol, 27, 6000, 10.1200/JCO.2009.23.6067 D'Amico, 2011, Risk-based management of prostate cancer, New Engl J Med, 365, 169, 10.1056/NEJMe1103829 Schemper, 1990, Efficient evaluation of treatment effects in the presence of missing covariate values, Stat Med, 9, 777, 10.1002/sim.4780090707 Geskus, 2011, Cause-specific cumulative incidence estimation and the fine and gray model under both left truncation and right censoring, Biometrics, 67, 39, 10.1111/j.1541-0420.2010.01420.x Krahn, 2002, The ten-year rule revisited: accuracy of clinicians' estimates of life expectancy in patients with localized prostate cancer, Urology, 60, 258, 10.1016/S0090-4295(02)01712-0 Albertsen, 1998, Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer, J Am Med Assoc, 280, 975, 10.1001/jama.280.11.975 Daskivich, 2011, Overtreatment of men with low-risk prostate cancer and significant comorbidity, Cancer, 117, 2058, 10.1002/cncr.25751 Alibhai, 2003, Do older men benefit from curative therapy of localized prostate cancer?, J Clin Oncol, 21, 3318, 10.1200/JCO.2003.09.034 Post, 2001, The independent prognostic value of comorbidity among men aged < 75 years with localized prostate cancer: a population-based study, BJU Int, 87, 821, 10.1046/j.1464-410x.2001.02189.x Hamstra, 2011, Older age predicts decreased metastasis and prostate cancer-specific death for men treated with radiation therapy: meta-analysis of radiation therapy oncology group trials, Int J Radiat Oncol Biol Phys, 81, 1293, 10.1016/j.ijrobp.2010.07.2004 Litwin, 2007, Assessment of prognosis with the total illness burden index for prostate cancer: aiding clinicians in treatment choice, Cancer, 109, 1777, 10.1002/cncr.22615